

# Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses

Laurent Yvan-Charvet, Nan Wang, Alan R. Tall

**Abstract**—Atherosclerosis has been characterized as a chronic inflammatory response to cholesterol deposition in arteries, but the mechanisms linking cholesterol accumulation in macrophage foam cells to inflammation are poorly understood. Macrophage cholesterol efflux occurs at all stages of atherosclerosis and protects cells from free cholesterol and oxysterol-induced toxicity. The ATP-binding cassette transporters ABCA1 and ABCG1 are responsible for the major part of macrophage cholesterol efflux to serum or HDL in macrophage foam cells, but other less efficient pathways such as passive efflux are also involved. Recent studies have shown that the sterol efflux activities of ABCA1 and ABCG1 modulate macrophage expression of inflammatory cytokines and chemokines as well as lymphocyte proliferative responses. In macrophages, transporter deficiency causes increased signaling via various Toll-like receptors including TLR4. These studies have shown that the traditional roles of HDL and ABC transporters in cholesterol efflux and reverse cholesterol transport are mechanistically linked to antiinflammatory and immunosuppressive functions of HDL. The underlying mechanisms may involve modulation of sterol levels and lipid organization in cell membranes. (*Arterioscler Thromb Vasc Biol.* 2010;30:139-143.)

**Key Words:** ABC transporter ■ apoptosis ■ immune system ■ lipids ■ cholesterol ■ inflammation

The removal of excess cholesterol from macrophage foam cells by HDL and its principal apolipoprotein, apoA-1, is thought to be one of the key mechanisms underlying the atheroprotective properties of HDL.<sup>1,2</sup> Cholesterol accumulation in macrophage foam cells during atherogenesis induces inflammatory responses, apoptosis, and other adverse effects.<sup>3</sup> Accumulating evidence suggests that by promoting cholesterol and oxysterol efflux, HDL regulates all these cellular responses in macrophage foam cells.<sup>4</sup> ATP-binding cassette transporters ABCA1 and ABCG1 play a pivotal role in cholesterol efflux from macrophage foam cells. ABCA1 and ABCG1 show additive activity in promoting macrophage reverse cholesterol transport *in vivo*,<sup>5</sup> and combined deficiency of these transporters in bone marrow-derived hematopoietic cells leads to severe defects in cholesterol efflux to HDL, massive cholesteryl ester accumulation in macrophages, and accelerated atherogenesis in a susceptible background.<sup>6,7</sup> In addition, by modulating cholesterol homeostasis, ABCA1 and ABCG1 may be central to the antiapoptotic and antiinflammatory effects of HDL.<sup>4,8,9</sup> Cholesterol accumulation in the plasma membrane of *Abca1*<sup>-/-</sup> and *Abcg1*<sup>-/-</sup> macrophages has been shown to increase signaling of Toll-like receptors enhancing the inflammatory response to LPS or other TLR ligands.<sup>10-13</sup> As a consequence, mice lacking ABCA1 and ABCG1 accumulate prominent macrophage

foam cells in various tissues such as in the lung, liver, spleen, or thymus,<sup>6,14-17</sup> and in response to an inflammatory stimulus *Abcg1*<sup>-/-</sup> bone marrow transplanted mice revealed a profound inflammatory infiltrate in the adventitia and necrotic core region of atherosclerotic lesions.<sup>13</sup>

## ABC Transporters and Active Cholesterol Efflux

Although passive cholesterol diffusion accounts for a large part of the efflux of cholesterol from nonloaded macrophages, active cholesterol efflux from macrophage foam cells via ABCA1 and ABCG1 represents as much as 70% of the total cellular cholesterol efflux following cholesterol loading.<sup>6,7,18,19</sup>

## ABCA1 and Cholesterol Efflux to ApoA-I

Two distinct mechanisms have been proposed to explain ABCA1-mediated cholesterol efflux from macrophage to apoA-I. One is that apoA-I forms complexes with phospholipid and cholesterol at the cell surface in a process promoted by ABCA1 activity.<sup>20,21</sup> There is abundant evidence that ABCA1-mediated cholesterol efflux to apoA-I can occur at the plasma membrane.<sup>22-24</sup> The other is that apoA-I binds ABCA1 at the cell surface and is subsequently internalized and targeted to late endosomes, where apoA-I picks up lipids

Received June 11, 2009; revision accepted September 15, 2009.

From the Division of Molecular Medicine, Department of Medicine, Columbia University, New York (L.Y.C., N.W., A.R.T.).

Correspondence to Laurent Yvan-Charvet, Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032. E-mail ly2159@columbia.edu

© 2010 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.108.179283

and the apolipoprotein-lipid complexes are then resecreted from the cell by exocytosis.<sup>25–27</sup> Internalized ABCA1–apoA-I complexes have been localized within late endosomes. More decisively, a mutant version of ABCA1 containing a deletion of the PEST sequence within its cytoplasmic domain (PEST sequences are rich in proline, glutamic acid, serine, and threonine) showed defective internalization and trafficking to late endosome/lysosomes and defective cholesterol efflux to apoA-I after loading the late endosome/lysosome pool of cholesterol by AcLDL treatment.<sup>26</sup> In a novel mode of posttranscriptional regulation, apoA-I stabilizes ABCA1 by preventing its calpain-mediated degradation in a PEST sequence dependent fashion.<sup>28,29</sup> A recent study by Lu et al<sup>30</sup> helps to integrate these findings by showing that apoA-I stabilizes ABCA1 against calpain proteolysis after internalization of ABCA1. Although these mechanisms are not mutually exclusive, there is controversy as to which mechanism plays the dominant role in ABCA1-mediated cholesterol efflux from macrophages to apoA-I. Recent studies have confirmed internalization of apoA-I and its accumulation in the late endosome/lysosome compartments in ABCA1-expressing macrophages.<sup>30–32</sup> These studies also showed that the majority of the resecreted apoA-I had been degraded.<sup>31</sup> However, these studies were performed using macrophages without cholesterol loading in the endosomal system.<sup>30–32</sup> The mechanism governing the efflux after cholesterol loading, as pointed out by Oram<sup>33</sup> and described above, are likely different. Indeed, a recent study has confirmed that the retroendocytosis of ABCA1 was critical in promoting cholesterol efflux through the ABCA1–apoA-I axis when excess lipoprotein-derived cholesterol had accumulated within cells.<sup>34</sup> In contrast, this study also demonstrated that blocking retroendocytosis of ABCA1 did not affect cholesterol efflux from cells in the absence of cholesterol loading in agreement with previous studies.<sup>30–32</sup>

### **ABCG1 and Cholesterol Efflux to Mature HDL**

Despite increasing interest and extensive study on the role of ABCG1, relatively little is known about how this transporter promotes efflux of cholesterol to mature HDL. Wang et al showed that ABCG1 promotes efflux of cholesterol to a variety of acceptors, including HDL, LDL, phospholipid vesicles, and cyclodextrin without increasing the binding of lipoproteins to cells.<sup>35</sup> ABCG1 also promoted efflux of a broader spectrum of sterols including oxysterols such as 7-ketocholesterol,<sup>8</sup> whereas ABCG1 and ABCG4 together promote efflux of sterol intermediates from the cholesterol synthesis pathway such as desmosterol.<sup>36</sup> Interestingly, overexpression of ABCG1 increases efflux of not only cellular sterols but also, to some extent, cellular phospholipids.<sup>35,37,38</sup> Overexpression of ABCG1 results in increased cell membrane cholesterol pools available for efflux and increases the rate constant for efflux; efflux appears to be diffusional and unidirectional and is more efficient for smaller HDL particles.<sup>39</sup> Different models have been proposed to explain how ABCG1 promotes cholesterol efflux to HDL. One suggests that ABCG1 helps sterol molecules to overcome the energy barrier for entry into the hydrophilic water layer, perhaps by using ATP to promote protrusion of the cholesterol molecule

into water, followed by a transient collision with an acceptor.<sup>40</sup> A second model points to a function of ABCG1 as a phospholipid floppase,<sup>37</sup> promoting changes in the organization of plasma membrane phospholipids and subsequent attraction of sterols to the outer leaflet for diffusional efflux. Another possibility is that ABCG1 promotes flopping of cholesterol in liquid ordered regions of plasma membrane such that spontaneous flipping of sterol back to the inner membrane is not possible.


## **ABC Transporters and the Molecular Regulation of the Immune System**

### **ABC Transporters and Macrophage Inflammation**

HDL has potent antiinflammatory properties, including the ability to directly bind and sequester lipopolysaccharide,<sup>41,42</sup> suppressing activation of Toll-like receptor 4 (TLR4) signaling.<sup>43</sup> Recent studies have indicated additional direct cellular effects of HDL leading to suppression of inflammatory responses. By promoting cholesterol efflux, HDL has been proposed to inhibit cellular inflammatory signaling leading to inhibition of MCP-1 and CD11b expression and monocyte transmigration.<sup>44</sup> Several studies have shown that the increased lipid raft formation in macrophages with genetic deficiencies of ABCA1 or ABCG1<sup>10–13,45</sup> could account for the enhanced inflammatory responses, especially after treatment with LPS or other TLR ligands leading to enhanced signaling via Myd88-NFκB (Figure).<sup>10–13,15</sup> Replenishment or removal of cholesterol using cyclodextrin modulates the inflammatory response of macrophages deficient in ABCA1 or ABCG1, indicating that the increased inflammatory response is likely attributable to cholesterol accumulation in membranes (Figure).<sup>12,13</sup> We recently reported that by modulating membrane cholesterol, deficiency of ABCA1 or ABCG1 increased TLR4 cell surface expression (Figure).<sup>13</sup> ABCG1 appears to have a more potent role in modulating macrophage inflammatory response than ABCA1, perhaps reflecting a predominant role of this transporter in modulating the lipid composition of plasma membrane lipid rafts (liquid ordered domains).<sup>38</sup> Interestingly, this response was not specific for TLR4, because macrophages lacking ABCA1 and ABCG1 were also more susceptible to TLR2 and TLR3 ligands. TLR3, in contrast to TLR2 and TLR4, is localized to the endosomal compartment. Recently, Sun et al showed that free cholesterol accumulation in the endosomal compartment increased the inflammatory response in a Toll-like receptor-dependent fashion, with TLR3 playing the major role.<sup>46</sup> Together with the fact that ABCA1 plays a key role in removing cholesterol from the endosomal/lysosomal compartment, this suggests the hypothesis that there may be a unique role of ABCA1 in modulating inflammatory response initiated in late endosome/lysosomes (Figure).

### **ABC Transporters and Lymphocyte Proliferation**

Recently, Bensinger et al reported that Liver X Receptor (LXR) signaling coupled sterol metabolism to T-cell lymphocyte proliferation in an ABCG1-dependent fashion.<sup>47</sup> ApoA-I KO mice also develop T-cell proliferation and activation and features of autoimmunity when backcrossed into an LDL



**Figure.** Protective effects of HDL and ABC transporters on macrophage inflammatory response induced by Toll-like receptors. HDL promotes cholesterol efflux via ABCA1 and ABCG1, and these transporters modulate the fluidity of the plasma membrane as well lipid raft formation. This, in turn, modulates the Toll-like receptor 4 signaling pathway by lipopolysaccharide (LPS) involving the formation of a LPS complex in lipid raft consisting of surface molecules such as CD14 and MD2. ABCG1 has a more potent role in modulating macrophage inflammatory response than ABCA1, but maximal effects require the activity of both transporters, suggesting complementary roles of these transporters. This response was not specific of TLR4 because deficiency of ABCA1 and ABCG1 also enhanced other Toll-like receptor signaling such as TLR2 present at the cell surface. Subsequently, downstream signaling molecule such as Myd88 will control the activation of NF- $\kappa$ B and the inflammatory gene expression response. Activation of LXR can modulate the inflammatory response through transrepression of NF- $\kappa$ B, but this mechanism doesn't seem to be controlled by ABCA1 or ABCG1 activity. Free cholesterol accumulation in the endosomal compartment also modulated the inflammatory response by spontaneous activation of Toll-like receptors present in this compartment such as TLR3. By promoting cholesterol efflux from the late endosome compartment, ABCA1 may have a unique role in dampening inflammation.

receptor-deficient background.<sup>48</sup> Together these studies strongly suggest that HDL-mediated cholesterol efflux via LXR-regulated ABC transporters plays a key role in downmodulating lymphocyte proliferation and activation. Bensinger et al proposed that an increased cholesterol pool in the ER might stimulate lymphocyte proliferation in splenic LXR $\beta^{-/-}$  T-cells.<sup>47</sup> The anti-CD3 antibody stimulated T-cell proliferation triggered the induction of the oxysterol-metabolizing enzyme SULT2B1 allowing the transfer of sulfate groups to oxysterols that inactivates their binding to LXR and thus shuts down LXR-dependent ABCG1 expression and cholesterol transport. Induction of SULT2B1 expression occurred at the same time as enhanced SREBP-2

processing and increased cholesterol biosynthesis.<sup>47</sup> Together these 2 mechanisms (ie, increased sterol synthesis and decreased sterol efflux) likely help to conserve cellular cholesterol required for increased membrane synthesis during cell proliferation. Additional mechanisms may also be involved, such as changes in membrane lipid composition or organization that lead to enhanced growth factor receptor mediated signaling events.

### ABC Transporters and In Vivo Relevance of the Regulation of the Immune System: A Role in Atherosclerosis and Other Inflammatory Diseases

#### ABC Transporters and Atherosclerosis

Transplantation of bone marrow from *Abca1*<sup>-/-</sup> mice into *Ldlr*<sup>-/-</sup> or *apoE*<sup>-/-</sup> recipients caused an increase in atherosclerosis.<sup>49,50</sup> However, conflicting data have been reported as deficiency of ABCG1 in bone marrow cells resulted in either a modest increase<sup>51</sup> or decrease in atherosclerosis,<sup>52,53</sup> and total body ABCG1 overexpression also resulted in either no effect,<sup>54</sup> aggravation,<sup>55</sup> or protection against atherosclerosis.<sup>56</sup> ABCA1 and ABCG1 have complementary activities in mediating cholesterol efflux,<sup>57,58</sup> and both transporters are LXR target genes. Therefore, the effects of single transporter deficiency could be masked by the compensatory upregulation of the other transporter as a result of sterol accumulation and LXR activation.<sup>6,59</sup> Accordingly, in vivo measurements of macrophage reverse cholesterol transport have shown additive effects of ABCA1 and ABCG1,<sup>5</sup> and bone marrow transplantation from mice with combined deficiencies of ABCA1 and ABCG1 into *Ldl*-deficient mice revealed accelerated atherosclerosis.<sup>6</sup> However, in another similar study transplantation of double KO bone marrow into *Ldlr*<sup>-/-</sup> mice resulted in no change in atherosclerosis, most likely reflecting an unexpected decrease in VLDL and LDL levels in the double KO bone marrow transplant recipients.<sup>7</sup> The latter study was interpreted as showing a disproportionate increase in atherosclerosis given the degree of VLDL/LDL lowering. We have not observed such decreases in VLDL/LDL in *Abca1*<sup>-/-</sup>*Abcg1*<sup>-/-</sup> bone marrow-transplanted mice,<sup>6</sup> and the reasons for this discrepancy will require further studies. Interestingly, the *Ldlr* knockout recipient mice receiving bone marrow from *Abca1*<sup>-/-</sup>*Abcg1*<sup>-/-</sup> donor mice showed massive myocardial foam cell accumulation, as well as foam cell and inflammatory cell accumulation in other tissues such as intestine and spleen, most likely secondary to markedly increased overall and macrophage-specific inflammatory responses illustrating in vivo the relevance of ABCA1 and ABCG1 in dampening inflammation.<sup>6,7</sup>

#### ABC Transporters and Inflammatory Diseases

Mice lacking ABCA1 and ABCG1 accumulate inflammatory macrophage foam cells not only in the myocardium but also in various tissues such as in the lung, liver, spleen, or thymus.<sup>6,14,17</sup> Several investigators have focused on the lung because mice lacking ABCA1, with low plasma HDL levels, revealed pulmonary lipidosis and progressive disease with chronic inflammation,<sup>15,59</sup> and this was much more prominent

in mice lacking ABCG1, with normal plasma HDL levels.<sup>6,14</sup> The mechanism by which these transporters are involved in lung disease is thought to be similar to what has been described for atherosclerosis including enhanced Toll-like receptor-mediated macrophage inflammation,<sup>15,16</sup> Consistent with this inflammatory phenotype, mice lacking ABCA1 and ABCG1 featured an inflammatory blood pattern characterized by increased neutrophils and monocytes.<sup>7,13</sup> This suggests that by dampening inflammation, HDL may have a general beneficial effect on inflammatory diseases including atherosclerosis and perhaps some inflammatory pulmonary diseases. Overexpression of the human apoA-I transgene in mice resulted in lower cytokine levels and improved survival rates after LPS challenge compared to wild-type mice,<sup>60</sup> whereas reconstituted HDL has been shown to reduce LPS-induced inflammation in rabbit, dogs, and humans.<sup>61–64</sup> The beneficial effect of HDL is, at present, thought to be related to the LPS-neutralizing properties of HDL.<sup>41,42</sup> These findings suggest that raising HDL may be a valuable therapeutic approach for a broad range of inflammatory diseases possibly including the treatment of septic shock and some inflammatory lung diseases.

### Summary and Future Directions

The studies of mice and cells with genetic deficiencies of ABCA1 and ABCG1 have helped to clarify the roles of these transporters in cholesterol and oxysterol efflux from macrophage foam cells. These processes have been shown to be linked to inflammatory and immune responses.<sup>10–13,17,18,47,48</sup> In the future studies of mice with cell-specific knock-outs of transporters in mice of uniform genetic background may help to define the importance of the immune system effects in atherosclerosis and other inflammatory diseases of the lung and the underlying cellular mechanisms.

### Disclosures

None.

### Sources of Funding

This work was supported by grants from the NIH (HL54591) and American Heart Association Scientist Development Grant 095DG2160053 to L. Yvan-Charvet.

### References

1. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. *J Intern Med*. 2008;263:256–273.
2. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. *Nat Clin Pract Cardiovasc Med*. 2007;4:102–109.
3. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. *Arterioscler Thromb Vasc Biol*. 2005;25:2255–2264.
4. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. *Cell Metab*. 2008;7:365–375.
5. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. *J Clin Invest*. 2007;117:2216–2224.
6. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. *J Clin Invest*. 2007;117:3900–3908.

7. Out R, Hoekstra M, Habets K, Meurs I, de Waard V, Hildebrand RB, Wang Y, Chimini G, Kuiper J, Van Berkel TJ, Van Eck M. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. *Arterioscler Thromb Vasc Biol*. 2008;28:258–264.
8. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. *Proc Natl Acad Sci U S A*. 2007;104:15093–15098.
9. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. *Arterioscler Thromb Vasc Biol*. 2008;28:2071–2077.
10. Francone OL, Royer L, Boucher G, Haghpassand M, Freeman A, Brees D, Aiello RJ. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. *Arterioscler Thromb Vasc Biol*. 2005;25:1198–1205.
11. Koseki M, Hirano K, Masuda D, Ikegami C, Tanaka M, Ota A, Sandoval JC, Nakagawa-Toyama Y, Sato SB, Kobayashi T, Shimada Y, Ohno-Iwashita Y, Matsuura F, Shimomura I, Yamashita S. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor- $\alpha$  secretion in Abca1-deficient macrophages. *J Lipid Res*. 2007;48:299–306.
12. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, Willingham MC, Hiltbold EM, Mishra N, Maeda N, Parks JS. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. *J Biol Chem*. 2008;283:22930–22941.
13. Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, Ishibashi M, Li R, Wang N, Tall AR. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. *Circulation*. 2008;118:1837–1847.
14. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. *Cell Metab*. 2005;1:121–131.
15. Baldan A, Gomes AV, Ping P, Edwards PA. Loss of ABCG1 results in chronic pulmonary inflammation. *J Immunol*. 2008;180:3560–3568.
16. Wojcik AJ, Skafflen MD, Srinivasan S, Hedrick CC. A critical role for ABCG1 in macrophage inflammation and lung homeostasis. *J Immunol*. 2008;180:4273–4282.
17. Out R, Jessup W, Le Goff W, Hoekstra M, Gelissen IC, Zhao Y, Kritharides L, Chimini G, Kuiper J, Chapman MJ, Huby T, Van Berkel TJ, Van Eck M. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. *Circ Res*. 2008;102:113–120.
18. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. *Arterioscler Thromb Vasc Biol*. 2007;27:1132–1138.
19. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. *J Lipid Res*. 2007;48:2453–2462.
20. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. *J Biol Chem*. 2000;275:33053–33058.
21. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. *J Biol Chem*. 2000;275:34508–34511.
22. Vaughan AM, Oram JF. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. *J Lipid Res*. 2003;44:1373–1380.
23. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. *J Biol Chem*. 2007;282:25123–25130.
24. Nandi S, Ma L, Denis M, Karwatsky J, Li Z, Jiang XC, Zha X. ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity. *J Lipid Res*. 2009;50:456–466.

25. Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. *Proc Natl Acad Sci U S A*. 1999;96:11358–11363.
26. Chen W, Sun Y, Welch C, Gorelik A, Leventhal AR, Tabas I, Tall AR. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. *J Biol Chem*. 2001;276:43564–43569.
27. Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, Comly S, Dwyer NK, Zhang M, Blanchette-Mackie J, Santamarina-Fojo S, Brewer HB Jr. Cellular localization and trafficking of the human ABCA1 transporter. *J Biol Chem*. 2001;276:27584–27590.
28. Chen W, Wang N, Tall AR. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. *J Biol Chem*. 2005;280:29277–29281.
29. Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall AR. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. *J Clin Invest*. 2003;111:99–107.
30. Lu R, Arakawa R, Ito-Osumi C, Iwamoto N, Yokoyama S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. *Arterioscler Thromb Vasc Biol*. 2008;28:1820–1824.
31. Faulkner LE, Panagotopoulos SE, Johnson JD, Woollett LA, Hui DY, Witting SR, Maiorano JN, Davidson WS. An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages. *J Lipid Res*. 2008;49:1322–1332.
32. Denis M, Landry YD, Zha X. ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. *J Biol Chem*. 2008;283:16178–16186.
33. Oram JF. The ins and outs of ABCA1. *J Lipid Res*. 2008;49:1150–1151.
34. Azuma Y, Takada M, Shin HW, Kioka N, Nakayama K, Ueda K. Retroendocytosis pathway of ABCA1/apoA-I contributes to HDL formation. *Genes Cells*. 2009;14:191–204.
35. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci U S A*. 2004;101:9774–9779.
36. Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. *FASEB J*. 2008;22:1073–1082.
37. Kobayashi A, Takanezawa Y, Hirata T, Shimizu Y, Misasa K, Kioka N, Arai H, Ueda K, Matsuo M. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. *J Lipid Res*. 2006;47:1791–1802.
38. Sano O, Kobayashi A, Nagao K, Kumagai K, Kioka N, Hanada K, Ueda K, Matsuo M. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. *J Lipid Res*. 2007;48:2377–2384.
39. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, Rothblat GH. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. *J Lipid Res*. 2009;50:275–284.
40. Small DM. Role of ABC transporters in secretion of cholesterol from liver into bile. *Proc Natl Acad Sci U S A*. 2003;100:4–6.
41. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. *Infect Immun*. 1993;61:5140–5146.
42. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. *Infect Immun*. 1995;63:253–258.
43. Takeda K, Akira S. Toll-like receptors in innate immunity. *Int Immunol*. 2005;17:1–14.
44. Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. *Shock*. 1997;7:175–181.
45. Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, Zha X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. *J Biol Chem*. 2006;281:36091–36101.
46. Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, Fitzgerald KA, Samokhin AO, Wang Y, Sayers S, Aikawa M, Jerome WG, Ostrowski MC, Bromme D, Libby P, Tabas IA, Welch CL, Tall AR. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. *Circ Res*. 2009;104:455–465.
47. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. *Cell*. 2008;134:97–111.
48. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. *Arterioscler Thromb Vasc Biol*. 2009;29:843–849.
49. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. *Arterioscler Thromb Vasc Biol*. 2002;22:630–637.
50. van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, Bottcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ, Schmitz G. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. *Proc Natl Acad Sci U S A*. 2002;99:6298–6303.
51. Out R, Hoekstra M, Hildebrand RB, Kruit JK, Meurs I, Li Z, Kuipers F, Van Berkel TJ, Van Eck M. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol*. 2006;26:2295–2300.
52. Baldan A, Pei L, Lee R, Tarr P, Tangirala RK, Weinstein MM, Frank J, Li AC, Tontonoz P, Edwards PA. Impaired development of atherosclerosis in hyperlipidemic Ldlr<sup>-/-</sup> and ApoE<sup>-/-</sup> mice transplanted with Abcg1<sup>-/-</sup> bone marrow. *Arterioscler Thromb Vasc Biol*. 2006;26:2301–2307.
53. Ranalletta M, Wang N, Han S, Yvan-Charvet L, Welch C, Tall AR. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1<sup>-/-</sup> bone marrow. *Arterioscler Thromb Vasc Biol*. 2006;26:2308–2315.
54. Burgess B, Naus K, Chan J, Hirsch-Reinshagen V, Tansley G, Matzke L, Chan B, Wilkinson A, Fan J, Donkin J, Balik D, Tanaka T, Ou G, Dyer R, Innis S, McManus B, Lutjohann D, Wellington C. Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice. *Arterioscler Thromb Vasc Biol*. 2008;28:1731–1737.
55. Basso F, Amar MJ, Wagner EM, Vaisman B, Paigen B, Santamarina-Fojo S, Remaley AT. Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. *Biochem Biophys Res Commun*. 2006;351:398–404.
56. Out R, Hoekstra M, Meurs I, de Vos P, Kuiper J, Van Eck M, Van Berkel TJ. Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. *Arterioscler Thromb Vasc Biol*. 2007;27:594–599.
57. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, Cartland S, Packianathan M, Kritharides L, Jessup W. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. *Arterioscler Thromb Vasc Biol*. 2006;26:534–540.
58. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. *J Lipid Res*. 2006;47:2433–2443.
59. Bates SR, Tao JQ, Collins HL, Francone OL, Rothblat GH. Pulmonary abnormalities due to ABCA1 deficiency in mice. *Am J Physiol Lung Cell Mol Physiol*. 2005;289:L980–L989.
60. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. *Proc Natl Acad Sci U S A*. 1993;90:12040–12044.
61. Casas AT, Hubsch AP, Rogers BC, Doran JE. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha. *J Surg Res*. 1995;59:544–552.
62. Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. *J Lab Clin Med*. 1995;126:548–558.
63. Quezado ZM, Natanson C, Banks SM, Alling DW, Koev CA, Danner RL, Elin RJ, Hosseini JM, Parker TS, Levine DM, et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock. *J Pharmacol Exp Ther*. 1995;272:604–611.
64. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. *J Exp Med*. 1996;184:1601–1608.